

Fig. 2. PIM1 expression level in breast cancer patients. (A) PIM1 overexpression in benign breast lesions and malignant breast cancer compared with healthy controls. (B) Fold change in PIM1 expression stratified by patient age. (C) PIM1 expression according to menopausal status. (D) Fold change in PIM1 expression categorized by body mass index (BMI, kg/m²)




Fig. 3. Serum Leptin (LEP) levels assessment at breast cancer presentation. (A) Significantly elevated (*p < 0.001) LEP levels in patients with breast cancer in comparison to benign breast lesions and healthy controls. (B) LEP levels stratified by patient age. (C) LEP levels according to menopausal status. (D) LEP levels categorized by body mass index (BMI, kg/m²) at diagnosis in early-stage breast cancer cases




Fig. 4. Serum Interleukin-20 (IL-20) serum levels assessment at breast cancer presentation. (A) Comparison of serum IL-20 levels in malignant breast cancer, benign breast lesions, and healthy individuals. (B) IL-20 levels stratified by patient age at diagnosis. (C) IL-20 levels according to menstrual cycle status. (D) IL-20 levels categorized by body mass index (BMI, kg/m²)